Document type
ArticleVersion
Published versionPublication date
All rights reserved
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/55786
Response to topical clonazepam in patients with burning mouth syndrome: a clinical study
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
Burning Mouth Syndrome (BMS) is a difficult disease for patients and clinicians. Moreover, there is not a general consensus on how to treat the disease. The main objective of this paper is to evaluate BMS patients' response to topical clonazepam treatment. A double blind study was performed. Among a total of 66 patients, 33 were treated with tablets of clonazepam and another 33 were treated with a placebo. Symptoms were evaluated after 1 month and 6 months of treatment and scored on an analogical scale from 0 to 10. Among the 33 patients treated with clonazepam, 23 showed at least a 50% reduction in symptoms after 1 month of treatment. On the contrary, only 4 in the placebo group exhibited significant improvement. After 6 months, significant differences were observed again, as 23 of the 33 patients treated with the drug reported at least a 50% reduction in symptoms, whereas only 2 among those treated with the placebo significantly improved. However, when measured in terms of a complete cure (lack of symptoms), the differences were not significant: 5 drug-treated patients and one belonging to the placebo group were asymptomatic after one month of treatment. In summary, it seems that clonazepam applied topically was effective in treating BMS in a large proportion of patients
Subject (English)
Citation
Citation
RODRÍGUEZ DE RIVERA CAMPILLO, Ma Eugenia, LÓPEZ LÓPEZ, José and CHIMENOS KÜSTNER, Eduardo. Response to topical clonazepam in patients with burning mouth syndrome: a clinical study. Bulletin du GIRSO. 2010. Vol. 49, num. 1, pags. 19-29. ISSN 0250-4693. [consulted: 11 of August of 2026]. Available at: https://hdl.handle.net/2445/55786